Development of an Optimal Antibiotic Regime for Long-term Therapy in Stable Chronic Obstructive Pulmonary Disease (COPD)

• Status: Unknown status
• Trial end date: 2013-04-01

Summary

Chronic Obstructive Pulmonary Disease (COPD) is the cause of considerable deaths, and exacerbations (flare up of symptoms) are a major cause of hospital admission in the UK. Bacterial infections play an important role in the development of COPD, however, there is little information available about the use of long term antibiotics in the treatment of this disease. Therefore the purpose of this study is to identify the best antibiotic regime for treating patients with COPD who have persistent bacterial infection in their lung. We will test a variety of approaches including both older and newer regimes prescribed either on a daily basis at a lower dose or in "pulsed" courses (for example, every other day or five days every month). The three antibiotics tested in this study are: moxifloxacin, azithromycin and doxycycline. This is a 13 weeks study conducted at the Royal Free Hospital, London. It is expected that approximately 200 patients will be selected for this study. The information we get from this study may help us to treat future patients with COPD better.

• Phase: Phase 3

Details

• Lead Sponsor: University College, London
• Collaborators: National Institute for Health Research, United Kingdom; Royal Free Hampstead NHS Trust; University of Cambridge
• Treatments: Anti-Bacterial Agents; Azithromycin; Doxycycline; Fluoroquinolones; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination